PAPADOPOULOS STELIOS
Insider CIK 1202098 · BGMD Director · RGLS Director · OVID Director · EUCR Director, 10% owner · BIIB Director · EXEL Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EXEL EXELIXIS, INC. | A Award | 2026-05-27 | 2026-05-29 | 8,367 | — | $0 | 1,197,595 | SEC↗ |
| OVID Ovid Therapeutics Inc. | A Award | 2026-04-07 | 2026-04-09 | 17,578 | $2.56 | $45.0K | 217,578 | SEC↗ |
| OVID Ovid Therapeutics Inc. | A Award deriv | 2026-02-26 | 2026-03-02 | 65,000 | — | $0 | 65,000 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2025-11-12 | 2025-11-13 | 100,000 | $43.55 | $4.36M | 1,189,228 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 15,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 4,650 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 2,325 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 4,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 9,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 30,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 30,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 60,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 59,514 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer | 2025-06-25 | 2025-06-27 | 64,635 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | U Tender | 2025-06-25 | 2025-06-27 | 976,253 | — | $0 | 64,635 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2025-05-29 | 2025-05-30 | 9,812 | — | $0 | 1,289,228 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2025-05-15 | 2025-05-16 | 20,634 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2025-05-15 | 2025-05-16 | 15,874 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2025-05-15 | 2025-05-16 | 20,634 | $44.35 | $915.1K | 1,279,416 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2025-05-15 | 2025-05-16 | 15,874 | $20.50 | $325.4K | 1,295,290 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2025-05-15 | 2025-05-16 | 15,874 | $44.35 | $704.0K | 1,279,416 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2025-05-15 | 2025-05-16 | 20,634 | $19.77 | $407.9K | 1,300,050 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2025-04-30 | 2025-04-30 | 62,500 | — | $0 | 1,040,888 | SEC↗ |
| OVID Ovid Therapeutics Inc. | A Award deriv | 2025-03-03 | 2025-03-04 | 90,000 | — | $0 | 90,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2024-05-31 | 2024-06-04 | 18,838 | — | $0 | 1,279,416 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2024-05-20 | 2024-05-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2024-05-20 | 2024-05-22 | 11,686 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2024-05-20 | 2024-05-22 | 11,437 | $21.00 | $240.2K | 1,260,578 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2024-05-20 | 2024-05-22 | 11,686 | $19.57 | $228.7K | 1,272,015 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2024-05-16 | 2024-05-17 | 30,000 | — | $0 | 30,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2024-03-14 | 2024-03-15 | 250,000 | $1.60 | $400.0K | 978,388 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2023-08-10 | 2023-08-14 | 15,000 | — | $0 | 15,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2023-06-13 | 2023-06-13 | 30,000 | — | $0 | 30,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2023-06-01 | 2023-06-02 | 20,718 | — | $0 | 1,260,329 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2023-04-13 | 2023-04-14 | 222,198 | $0.90 | $200.0K | 728,388 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2022-06-15 | 2022-06-17 | 2,255 | — | $0 | 10,095 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2022-06-09 | 2022-06-10 | 90,000 | — | $0 | 90,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2022-05-26 | 2022-05-27 | 19,575 | — | $0 | 1,239,611 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2022-02-22 | 2022-02-24 | 84,515 | $19.56 | $1.65M | 1,220,036 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2021-11-30 | 2021-12-01 | 2,222,222 | $0.36 | $800.0K | 5,061,929 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2021-07-01 | 2021-07-02 | 1,275 | — | $0 | 7,840 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2021-06-14 | 2021-06-15 | 40,000 | — | $0 | 40,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2021-05-27 | 2021-05-28 | 16,424 | — | $0 | 1,304,551 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2021-05-11 | 2021-05-13 | 40,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2021-05-11 | 2021-05-13 | 40,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2021-05-11 | 2021-05-13 | 40,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2021-05-11 | 2021-05-13 | 40,000 | $3.38 | $135.2K | 1,293,600 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2021-05-11 | 2021-05-13 | 5,473 | $25.01 | $136.9K | 1,288,127 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2021-05-11 | 2021-05-13 | 5,075 | $25.00 | $126.9K | 1,253,600 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2021-05-11 | 2021-05-13 | 40,000 | $6.30 | $252.0K | 1,228,897 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2021-05-11 | 2021-05-13 | 40,000 | $3.13 | $125.2K | 1,258,675 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2021-05-11 | 2021-05-13 | 10,222 | $24.95 | $255.0K | 1,218,675 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2020-12-04 | 2021-01-27 | 793,528 | $0.63 | $499.9K | 2,839,707 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2020-12-04 | 2020-12-07 | 595,146 | $0.13 | $77.4K | 595,146 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2020-12-04 | 2020-12-07 | 793,528 | $0.63 | $499.9K | 1,986,729 | SEC↗ |
| EUCR Eucrates Biomedical Acquis | J Other | 2020-11-24 | 2020-11-27 | 255,094 | — | $0 | 2,619,906 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2020-06-17 | 2020-06-19 | 23,250 | — | $0 | 23,250 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2020-06-03 | 2020-06-05 | 1,470 | — | $0 | 6,565 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2020-05-21 | 2020-05-22 | 15,538 | — | $0 | 1,188,897 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2020-05-13 | 2020-05-15 | 120,791 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2020-05-13 | 2020-05-15 | 120,791 | $5.82 | $703.0K | 1,173,359 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2020-05-08 | 2020-05-08 | 30,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2020-05-08 | 2020-05-08 | 15,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2020-05-08 | 2020-05-08 | 15,000 | $5.92 | $88.8K | 1,097,568 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2020-05-08 | 2020-05-08 | 30,000 | $4.58 | $137.4K | 1,082,568 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2020-05-08 | 2020-05-08 | 45,000 | $25.84 | $1.16M | 1,052,568 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | C Conversion deriv | 2020-02-03 | 2020-02-04 | 84,632 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | C Conversion | 2020-02-03 | 2020-02-04 | 846,320 | — | $0 | 2,039,521 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2019-12-24 | 2019-12-26 | 84,632 | $6.66 | $563.6K | 84,632 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2019-12-24 | 2019-12-26 | 846,320 | $0.13 | $110.0K | 846,320 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2019-10-10 | 2019-10-15 | 46,500 | — | $0 | 46,500 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2019-06-19 | 2019-06-20 | 1,905 | — | $0 | 5,095 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2019-05-23 | 2019-05-24 | 20,634 | — | $0 | 20,634 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2019-05-23 | 2019-05-24 | 10,317 | — | $0 | 1,052,568 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy deriv | 2019-05-07 | 2019-05-08 | 370,370 | $0.13 | $48.1K | 370,370 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2019-05-07 | 2019-05-21 | 370,370 | $0.13 | $48.1K | 370,370 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2019-05-07 | 2019-05-08 | 370,370 | $1.08 | $400.0K | 1,189,872 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2019-05-07 | 2019-05-21 | 370,370 | $1.08 | $400.0K | 1,189,872 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2019-02-21 | 2019-02-22 | 11,250 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2019-02-21 | 2019-02-22 | 15,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2019-02-21 | 2019-02-22 | 26,250 | $21.25 | $557.8K | 1,042,251 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2019-02-21 | 2019-02-22 | 15,000 | $4.57 | $68.5K | 1,068,501 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2019-02-21 | 2019-02-22 | 11,250 | $4.16 | $46.8K | 1,053,501 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2018-12-28 | 2019-01-02 | 50,000 | $1.09 | $54.5K | 835,073 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2018-12-27 | 2018-12-28 | 26,401 | $1.04 | $27.5K | 785,073 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2018-12-26 | 2018-12-28 | 90,000 | $0.95 | $85.5K | 758,672 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2018-11-16 | 2018-11-19 | 300,000 | $1.38 | $414.0K | 668,672 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2018-11-15 | 2018-11-19 | 200,000 | $1.33 | $266.0K | 368,672 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 152 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 1,458 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 1,458 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 1,458 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 3,051 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 2,500 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 6,250 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2018-11-12 | 2018-11-21 | 4,583 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2018-11-12 | 2018-11-21 | 20,910 | — | $0 | 168,672 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2018-06-12 | 2018-06-14 | 1,450 | — | $0 | 3,190 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2018-06-01 | 2018-06-05 | 55,000 | — | $0 | 55,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2018-05-24 | 2018-05-24 | 15,874 | — | $0 | 15,874 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2018-05-24 | 2018-05-24 | 7,937 | — | $0 | 1,042,251 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2018-05-17 | 2018-05-21 | 75,000 | — | $0 | 75,000 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2018-05-07 | 2018-05-07 | 15,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2018-05-07 | 2018-05-07 | 15,000 | $22.15 | $332.3K | 1,034,314 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2018-05-07 | 2018-05-07 | 15,000 | $11.66 | $174.9K | 1,049,314 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2018-03-02 | 2018-03-02 | 15,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2018-03-02 | 2018-03-02 | 15,000 | $7.97 | $119.5K | 1,049,314 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2018-03-02 | 2018-03-02 | 15,000 | $24.05 | $360.8K | 1,034,314 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2017-12-04 | 2017-12-06 | 96,629 | $0.89 | $86.0K | 1,797,306 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2017-09-22 | 2017-09-22 | 10,000 | $25.40 | $254.0K | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2017-09-19 | 2017-09-20 | 127,790 | $27.63 | $3.53M | 1,034,314 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2017-09-18 | 2017-09-20 | 72,210 | $27.76 | $2.00M | 1,162,104 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2017-07-25 | 2017-07-25 | 1,000,000 | $0.91 | $910.0K | 1,770,677 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2017-06-07 | 2017-06-09 | 1,740 | — | $0 | 19,946 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2017-06-01 | 2017-06-02 | 30,000 | — | $0 | 30,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2017-05-25 | 2017-05-26 | 11,686 | — | $0 | 11,686 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2017-05-25 | 2017-05-30 | 11,686 | — | $0 | 11,686 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2017-05-25 | 2017-05-26 | 5,843 | — | $0 | 1,234,314 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2017-05-25 | 2017-05-30 | 5,843 | — | $0 | 1,234,314 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2017-03-22 | 2017-03-23 | 300,000 | $1.23 | $369.0K | 700,677 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2017-03-21 | 2017-03-23 | 200,000 | $1.20 | $240.0K | 400,677 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise deriv | 2017-03-20 | 2017-03-21 | 10,000 | — | $0 | 0 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2017-03-20 | 2017-03-21 | 10,000 | $21.66 | $216.6K | 1,228,471 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2017-03-20 | 2017-03-21 | 10,000 | $10.53 | $105.3K | 1,238,471 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2016-06-08 | 2016-06-09 | 1,590 | — | $0 | 18,170 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2016-06-02 | 2016-06-03 | 36,620 | — | $0 | 36,620 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2016-05-26 | 2016-05-26 | 40,000 | — | $0 | 40,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2016-01-04 | 2016-01-05 | 15,071 | — | $0 | 1,228,471 | SEC↗ |
| BGMD BG Medicine, Inc. | A Award deriv | 2015-11-18 | 2015-11-20 | 5,000 | — | $0 | 5,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise deriv | 2015-08-07 | 2015-08-07 | 15,677 | — | $0 | 1,823 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise deriv | 2015-08-07 | 2015-08-07 | 17,500 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise deriv | 2015-08-07 | 2015-08-07 | 17,500 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise | 2015-08-07 | 2015-08-07 | 15,677 | $2.66 | $41.7K | 200,677 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise | 2015-08-07 | 2015-08-07 | 17,500 | $0.38 | $6.7K | 167,500 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise | 2015-08-07 | 2015-08-07 | 17,500 | $1.74 | $30.4K | 185,000 | SEC↗ |
| BIIB BIOGEN INC. | P Buy | 2015-07-27 | 2015-07-27 | 5,000 | $304.98 | $1.52M | 5,000 | SEC↗ |
| BIIB BIOGEN INC. | P Buy | 2015-07-27 | 2015-07-27 | 5,000 | $304.78 | $1.52M | 5,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2015-06-10 | 2015-06-26 | 17,500 | — | $0 | 17,500 | SEC↗ |
| BIIB BIOGEN INC. | A Award | 2015-06-10 | 2015-06-11 | 1,040 | — | $0 | 16,580 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2015-05-28 | 2015-05-28 | 40,000 | — | $0 | 40,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise deriv | 2014-12-12 | 2014-12-15 | 150,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | M Exercise | 2014-12-12 | 2014-12-15 | 150,000 | $0.38 | $57.0K | 150,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2014-10-14 | 2014-10-16 | 69,444 | — | $0 | 1,213,400 | SEC↗ |
| BIIB BIOGEN IDEC INC. | A Award | 2014-06-12 | 2014-06-16 | 870 | — | $0 | 15,105 | SEC↗ |
| BIIB BIOGEN IDEC INC. | A Award | 2014-06-12 | 2014-06-16 | 435 | — | $0 | 15,540 | SEC↗ |
| BGMD BG Medicine, Inc. | A Award deriv | 2014-06-03 | 2014-06-05 | 4,205 | — | $0 | 4,205 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2014-05-29 | 2014-05-30 | 40,000 | — | $0 | 40,000 | SEC↗ |
| """RGLS""" Regulus Therapeutics Inc. | A Award deriv | 2014-05-22 | 2014-05-22 | 17,500 | — | $0 | 17,500 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2013-12-06 | 2013-12-09 | 120,791 | — | $0 | 120,791 | SEC↗ |
| BGMD BG Medicine, Inc. | A Award deriv | 2013-06-12 | 2013-06-14 | 4,205 | — | $0 | 4,205 | SEC↗ |
| BIIB BIOGEN IDEC INC. | A Award | 2013-06-12 | 2013-06-13 | 1,305 | — | $0 | 14,235 | SEC↗ |
| BIIB BIOGEN IDEC INC. | S Sale | 2013-06-11 | 2013-06-13 | 2,020 | $219.62 | $443.6K | 12,930 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2013-06-10 | 2013-06-10 | 17,500 | — | $0 | 17,500 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2013-05-23 | 2013-05-24 | 30,000 | — | $0 | 30,000 | SEC↗ |
| BIIB BIOGEN IDEC INC. | M Exercise deriv | 2013-03-11 | 2013-03-12 | 35,000 | — | $0 | 0 | SEC↗ |
| BIIB BIOGEN IDEC INC. | M Exercise deriv | 2013-03-11 | 2013-03-12 | 5,700 | — | $0 | 0 | SEC↗ |
| BIIB BIOGEN IDEC INC. | M Exercise deriv | 2013-03-11 | 2013-03-12 | 5,975 | — | $0 | 0 | SEC↗ |
| BIIB BIOGEN IDEC INC. | S Sale | 2013-03-11 | 2013-03-12 | 31,034 | $172.08 | $5.34M | 18,916 | SEC↗ |
| BIIB BIOGEN IDEC INC. | M Exercise | 2013-03-11 | 2013-03-12 | 5,700 | $59.17 | $337.3K | 20,650 | SEC↗ |
| BIIB BIOGEN IDEC INC. | S Sale | 2013-03-11 | 2013-03-12 | 3,966 | $172.72 | $685.0K | 14,950 | SEC↗ |
| BIIB BIOGEN IDEC INC. | S Sale | 2013-03-11 | 2013-03-12 | 5,700 | $172.45 | $983.0K | 14,950 | SEC↗ |
| BIIB BIOGEN IDEC INC. | M Exercise | 2013-03-11 | 2013-03-12 | 35,000 | $59.17 | $2.07M | 49,950 | SEC↗ |
| BIIB BIOGEN IDEC INC. | S Sale | 2013-03-11 | 2013-03-12 | 5,975 | $172.67 | $1.03M | 14,950 | SEC↗ |
| BIIB BIOGEN IDEC INC. | M Exercise | 2013-03-11 | 2013-03-12 | 5,975 | $53.43 | $319.2K | 20,925 | SEC↗ |
| BGMD BG Medicine, Inc. | P Buy | 2013-01-30 | 2013-02-01 | 250,000 | $2.00 | $500.0K | 1,187,713 | SEC↗ |
| BGMD BG Medicine, Inc. | A Award deriv | 2012-06-11 | 2012-06-13 | 4,205 | — | $0 | 4,205 | SEC↗ |
| BIIB BIOGEN IDEC INC. | A Award | 2012-06-08 | 2012-06-11 | 2,020 | — | $0 | 14,950 | SEC↗ |
| EXEL EXELIXIS INC | A Award deriv | 2012-05-24 | 2012-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| BGMD BG Medicine, Inc. | A Award deriv | 2012-02-27 | 2012-02-29 | 4,205 | — | $0 | 4,205 | SEC↗ |